Publications and Congresses
The information in this section may include content beyond what is in the FDA-approved label. Because the FDA has not approved such content, no conclusions regarding safety or efficacy may be made. Providing this information should not be construed as recommendation for use of a Genentech product for unapproved uses. For FDA-approved products please consult the product’s full prescribing information for a complete discussion of risks and benefits of the product(s) for its approved indication(s).
Publications: The list of publications is not an exhaustive list of published materials on the product. The list of references by data topics is selected per evidence-based medicine criteria. To browse a full listing of published scientific literature:
Congresses: The list of congresses is a subset of Roche/Genentech posters and oral presentations for the product with data presented at scientific meetings in the recent 24 months. To browse full Roche/Genentech congress presentations and posters:
Showing 68 out of 68 results
-
20240901 Characteristics of patients with chronic spontaneous urticaria who are late-responders to omalizumab
Mosnaim G, Casale T, Holden M, et al. Characteristics of patients with chronic spontaneous urticaria who are late-responders to omalizumab 2024;12(9):2537-2539.Chronic Spontaneous UrticariaSupportive Studies -
20240901 Does comorbid food allergy affect response to omalizumab in patients with asthma?
Fiocchi A, Chinthrahah R, Ansotegui I, et al. Does Comorbid Food Allergy Affect Response to Omalizumab in Patients with Asthma? 2024;17:889-900.Food AllergySupportive Studies -
20240801 Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab?
Casale T, Trzaskoma B, Holden M, et al. Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab? 2024;17(8):1-4.Chronic Spontaneous UrticariaSafety -
20240601 Real-world outcomes in patients with chronic spontaneous urticaria receiving omalizumab: insights from a clinical practice survey
Seetasith A, Holden M, Hetherington J, et al. Real-world outcomes in patients with chronic spontaneous urticaria receiving omalizumab: insights from a clinical practice survey 2024;40(6):1059-1066.Chronic Spontaneous UrticariaReal World Experience (RWE) -
20240301 Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma
Chase N, Littlejohn M, Holweg C, et al. Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma 2024;223:1-4.Allergic AsthmaSupportive Studies -
20240301 Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status
Gevaert P, Mullol J, Saenz R, et al. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status 2024;132(3):355-362.Chronic Rhinosinusitis With Nasal PolypsExploratory Analysis -
20240225 Omalizumab for the Treatment of Multiple Food Allergies
Wood RA, Togias A, Sicherer SCH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. [online] 2024. https://doi.org/10.1056/NEJMoa2312382Food AllergyPivotal Trial(s) -
20240201 Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab
Casale T, Chipps B, Iqbal A, et al. Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab 2024;12(2):512-514.Allergic AsthmaSupportive Studies -
20240201 Impact of Patient Baseline Characteristics on Work Productivity and Activity Impairment Following Omalizumab Treatment in Patients With Allergic Asthma
Katial R, Creasy B, Trzaskoma B, et al. Impact of Patient Baseline Characteristics on Work Productivity and Activity Impairment Following Omalizumab Treatment in Patients With Allergic Asthma. Presented at the American Academy of Allergy Asthma & Immunology Annual Meeting; February 23-26; Washington, DCAllergic AsthmaSupportive Studies -
20240201 Hospitalizations and Emergency Department Visits Before and After Omalizumab Treatment in Patients With Asthma and Food Allergies
Bird JA, Wang J, Seetasith A, et al. Hospitalizations and Emergency Department Visits Before and After Omalizumab Treatment in Patients With Asthma and Food Allergies. Presented at the American Academy of Allergy Asthma & Immunology Annual Meeting; February 23-26; Washington, DCFood AllergyReal World Experience (RWE) -
20240201 Impact Of Food Allergy On Work Productivity And Healthcare Resource Use In Patients With Allergic Asthma Treated With Omalizumab
Sriaroon P, Ansotegui IJ, Fiocchi A, et al. Impact of Food Allergy on Work Productivity and Healthcare Resource Use in Patients With Allergic Asthma Treated With Omalizumab. Presented at the American Academy of Allergy Asthma & Immunology Annual Meeting; February 23-26; Washington, DCFood AllergySupportive Studies -
20240201 Factors Associated With Chronic Spontaneous Urticaria Diagnostic and Treatment Delay in Real-World Clinical Practice
Seetasith A, Hetherington J, Keal A, et al. Impact of Patient Baseline Characteristics on Work Productivity and Activity Impairment Following Omalizumab Treatment in Patients With Allergic Asthma. Presented at the American Academy of Allergy Asthma & Immunology Annual Meeting; February 23-26; Washington, DCChronic Spontaneous UrticariaReal World Experience (RWE) -
20240101 Omalizumab improves sleep and health status for patients with chronic rhinosinusitis with nasal polyps: An analysis of randomized clinical trials
Meltzer E, Mullol J, Ko J, et al. Omalizumab improves sleep and health status for patients with chronic rhinosinusitis with nasal polyps: An analysis of randomized clinical trials 2024;14(7):1163-1172.Chronic Rhinosinusitis With Nasal PolypsExploratory Analysis -
20231109 Impact of Baseline Characteristics on Long-term Response Following Omalizumab Treatment in Patients with Allergic Asthma
Katial R, Creasy B, Trzaskoma B, et al. Impact of Baseline Characteristics on Long-term Response Following Omalizumab Treatment in Patients with Allergic Asthma. Presented at the 2023 Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI).Allergic AsthmaSupportive Studies -
20231109 Omalizumab Use in Patients with Chronic Spontaneous Urticaria: A Real-World Survey in the United States
Holden M, Seetasith A, Hetherington, et al. Omalizumab Use in Patients with Chronic Spontaneous Urticaria: A Real-World Survey in the United States. Presented at the 2023 Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI).Chronic Spontaneous UrticariaReal World Experience (RWE) -
20231101 Time To Sleep Improvement In Patients With Chronic Spontaneous Urticaria Treated With Omalizumab
Mosnaim G, Holden M, Trzaskoma BL, et al. Time To Sleep Improvement In Patients With Chronic Spontaneous Urticaria Treated With Omalizumab. Presented at the 2023 Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI).Chronic Spontaneous UrticariaPivotal Trial(s) -
20231101 Omalizumab Use in Patients with Chronic Spontaneous Urticaria: A Real-World Survey in the United States
Holden M, Seetasith A, Hetherington J, et al. Omalizumab Use in Patients with Chronic Spontaneous Urticaria: A Real-World Survey in the United States. Presented at the 2023 Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI).Chronic Spontaneous UrticariaReal World Experience (RWE) -
20231101 Real-World Effectiveness of Omalizumab in Patients Treated for Chronic Spontaneous Urticaria
Garmo V, Seetasith A, Holden M, et al. Real-World Effectiveness of Omalizumab in Patients Treated for Chronic Spontaneous Urticaria. Presented at the 2023 Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI).Chronic Spontaneous UrticariaReal World Experience (RWE) -
20231101 Impact of Baseline Angioedema and IgE on Response to Omalizumab in Chronic Spontaneous Urticaria
Casale TB, Trzaskoma BL, Holden M, et al. Impact of Baseline Angioedema and IgE on Response to Omalizumab in Chronic Spontaneous Urticaria. Presented at the 2023 Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI).Chronic Spontaneous UrticariaPivotal Trial(s) -
20231001 Effect of omalizumab on adult outcomes in pediatric patients with asthma and food allergy.
Chinthrajah RS, Ansotegul IJ, Sriaroon P, et al. Effect of omalizumab on adult outcomes in pediatric patients with asthma and food allergy. Presented at the 2023 Annual Meeting of the American Academy of Pediatrics (AAP)Allergic AsthmaFood AllergyExploratory Analysis -
20230901 Similar response to omalizumab in children with allergic asthma from different racial backgrounds
Witonsky J, Elhawary J, Millette L, et al. Similar response to omalizumab in children with allergic asthma from different racial backgrounds 2023;11(9):2911-2913.Allergic AsthmaExploratory Analysis -
20230601 Antitussive Use in Patients with Inadequately Controlled Moderate-to-Severe Asthma: A Post Hoc Analysis of the Omalizumab EXTRA Trial
Rutland C, Iweala O, Anders K, et al. Antitussive Use in Patients with Inadequately Controlled Moderate-to-Severe Asthma: A Post Hoc Analysis of the Omalizumab EXTRA Trial 2023;24(16):661-665.Allergic AsthmaSupportive Studies -
20230501 Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps
Braid J, Islam L, Gugiu C, et al. Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps 2023;16(5):1-9.Chronic Spontaneous UrticariaExploratory Analysis -
20230224 Real-world Survey Outcomes for Chronic Spontaneous Urticaria for Patients on Omalizumab vs Patients Eligible for Omalizumab
Holden M, Bernstein JA, Seetasith A, et al. Real-world Survey Outcomes for Chronic Spontaneous Urticaria for Patients on Omalizumab vs Patients Eligible for Omalizumab. Presented at AAAAI 2023 Annual Meeting of the American College of Allergy, Asthma, and Immunology.Chronic Spontaneous UrticariaReal World Experience (RWE) -
20230201 Age of asthma onset does not impact the response to omalizumab
Rogers L, Holweg C, Pazwash H, et al. Age of asthma onset does not impact the response to omalizumab 2023;20:1-5.Allergic AsthmaExploratory Analysis -
20221110 Omalizumab Treatment of Chronic Spontaneous Urticaria: Effectiveness and Satisfaction Assessed by a Real-World Survey
Casale TB, Seetasith A, Hetherington J, et al. Omalizumab Treatment of Chronic Spontaneous Urticaria: Effectiveness and Satisfaction Assessed by a Real-World Survey. Presented at the 2022 Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI).Chronic Spontaneous UrticariaReal World Experience (RWE) -
20221110 Time to Clinically Meaningful Response to Omalizumab in Patients With Chronic Spontaneous Urticaria. Presented at the 2022 Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI).
Casale TB, Holden M, Trzaskoma BL, et al. Time to Clinically Meaningful Response to Omalizumab in Patients With Chronic Spontaneous Urticaria. Presented at the 2022 Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI).Chronic Spontaneous UrticariaExploratory Analysis -
20220720 Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
Wood RA, Chinthrajah RS, Rudman Spergel AK, et al. Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH). JACI Global. 2022Food AllergyPivotal Trial(s) -
20220501 Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma
Geng, Dixon A, Ko J, et al. Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma 2022;128(5):553-560.Allergic AsthmaExploratory Analysis -
20220301 Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study
Gevaert P, Saenz R, Corren J, et al. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study 2022; 149(3):957-965.Chronic Rhinosinusitis With Nasal PolypsExploratory Analysis -
20220101 Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA
Hanania N, Fortis S, Haselkorn T, et al. Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA 2022;10(1):222-228.Allergic AsthmaSupportive Studies -
20220101 Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis
Damask C, Chen M, Holweg C, et al. Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis 2022;36(1):135-141.Chronic Rhinosinusitis With Nasal PolypsExploratory Analysis -
20220101 Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis
Damask C, Chen M, Holweg CTJ, et al. Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis. Am J Rhinol Allergy. 2021 Aug 12:19458924211030486.Chronic Rhinosinusitis With Nasal PolypsPivotal Trial(s) -
20211201 Omalizumab and quality of life in nasal polyps: A post hoc analysis
Han J, Yoo B, Saenz R, et al. Omalizumab and quality of life in nasal polyps: A post hoc analysis 2022;12:1188-1190.Chronic Rhinosinusitis With Nasal PolypsExploratory Analysis -
20211101 Response to Omalizumab in Black and White Patients with Allergic Asthma
Szefler S, Jerschow E, Yoo B, et al. Response to Omalizumab in Black and White Patients with Allergic Asthma 2021;9(11):4021-4028.Allergic AsthmaSupportive Studies -
20210801 Omalizumab response in patients with asthma by number and type of allergen
Soong W, Yoo B, Pazwash H, et al. Omalizumab response in patients with asthma by number and type of allergen 2021;127(2):223-231.Allergic AsthmaSupportive Studies -
20210601 No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities
Chen M, Choo E, Yoo B, et al. No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities 2021;126(6):666-673.Allergic AsthmaSupportive Studies -
20200902 Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
Gevaert P, Omachi T, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials 2020;146(3):595-605.Chronic Rhinosinusitis With Nasal PolypsPivotal Trial(s) -
20200901 Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity
Szefler S, Casale T, Haselkorn T, et al. Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity 2020;8(8):2673-2680.Allergic AsthmaSupportive Studies -
20200201 Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort
Namazy J, Blais L, Andrews E, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort 2020;145(2):528-536.Allergic AsthmaSupportive Studies -
20200201 Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma
Busse W, Humbert M, Haselkorn T, et al. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma 2020;124(2):190-196.Allergic AsthmaSupportive Studies -
20200101 Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States
Sullivan P, Li Q, Bilar S, et al. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States 2020;36(1):23-32.Allergic AsthmaHealth Economics and Outcomes Research (HEOR) -
20200101 Plasma Galectin-3 and urine proteomics predict FEV1 improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study
Riccio A, Mauri P, De Ferrari L, et al. Plasma Galectin-3 and urine proteomics predict FEV1 improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study 2020;13(1):1-11.Allergic AsthmaSupportive Studies -
20190901 Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU)
Casale T, Murphy T, Holden M, et al. Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU) 2019;7(7);2487-2490.Chronic Spontaneous UrticariaSupportive Studies -
20190201 Racial Disparities in Asthma-Related Health Outcomes in Children with Severe/Difficult-to-Treat Asthma
Guilbert T, Zeiger R, Haselkorn T, et al. Racial Disparities in Asthma-Related Health Outcomes in Children with Severe/Difficult-to-Treat Asthma 2019;7(2):568-577.Allergic AsthmaSupportive Studies -
20190101 Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
Casale T, Luskin A, Busse W, et al. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study 2019;7(1):156-164.Allergic AsthmaReal World Experience (RWE) -
20180601 Validity and responsiveness of the Urticaria Activity and Impact Measure
Maurer M, Mathias S, Crosby R, et al. Validity and responsiveness of the Urticaria Activity and Impact Measure 2018;120(6):641-647.Chronic Spontaneous UrticariaSupportive Studies -
20180301 The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria
Maurer M, Kaplan A, Rosén K, et al. The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria 2018;141(3):1138-1139.Chronic Spontaneous UrticariaSupportive Studies -
20170401 Clinical features of adolescents with chronic idiopathic or spontaneous urticaria
Goldstein S, Gabriel S, Kianifard F, et al. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria 2017;118(4):500-504.Chronic Spontaneous UrticariaExploratory Analysis -
20160801 Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double‐blind, placebo‐controlled studies
Gimenéz-Arnau A, Spector S, Antonova E, et al. Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double‐blind, placebo‐controlled studies 2016;6(32):1-10.Chronic Spontaneous UrticariaExploratory Analysis -
20150901 Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy
Casale T, Bernstein J, Maurer M, et al. Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy 2015;3(5):743-750.Chronic Spontaneous UrticariaExploratory Analysis -
20150101 Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1-antihistamines: a randomized, placebo-controlled study
Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1-antihistamines: a randomized, placebo-controlled study [supplementary appendix appears online]. J Invest Dermatol. 2015;135:67-75.Chronic Spontaneous UrticariaPivotal Trial(s) -
20131013 Real-world Treatment Patterns for Chronic Spontaneous Urticaria: Is Omalizumab Associated With Reduced Corticosteroid Use?
Seetashith A, Reiss Reddy S, Garmo V, et al. Real-world Treatment Patterns for Chronic Spontaneous Urticaria: Is Omalizumab Associated With Reduced Corticosteroid Use? Presented at AMCP-NEXUS 2022.Chronic Spontaneous UrticariaReal World Experience (RWE) -
20130702 Omalizumab reduces the severity of chronic spontaneous urticaria: a real-world survey in the United States
Casale TB, Hetherington J, Hoskin B, et al. Omalizumab reduces the severity of chronic spontaneous urticaria: a real-world survey in the United States. Presented at the 2022 European Academy of Allergy and Clinical Immunology (EACCI) Congress.Chronic Spontaneous UrticariaReal World Experience (RWE) -
20130701 Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013:132(1):101-109.Chronic Spontaneous UrticariaPivotal Trial(s) -
20130701 Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132:101-109.Chronic Spontaneous UrticariaPivotal Trial(s) -
20130307 Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria
Maurer M, Rosén K, Hsieh H-J, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria [protocol appears online]. N Engl J Med 2013b;368:924-935.Chronic Spontaneous UrticariaSafety -
20130307 Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria
Maurer M, Rosén K, Hsieh H-J, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria [published erratum appears in: N Engl J Med 2013 Jun 13; 368(24):2340-1] [supplementary appendix appears online]. N Engl J Med 2013;368:924-935.Chronic Spontaneous UrticariaPivotal Trial(s) -
20130301 Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Maurer M, Rosén K, Hsieh H, et al. Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria 2013;368:924-935.Chronic Spontaneous UrticariaPivotal Trial(s) -
20110901 A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria
Saini S, Rosén K, Hsieh J, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria. J Allergy Clin Imunol 2011;128(3):567-573.Chronic Spontaneous UrticariaSupportive Studies -
20110101 Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma
Milgrom H, Fowler-Taylor A, Vidaurre CF, et al. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin 2011;27:163-169.Allergic AsthmaSafety -
20091201 Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009;124:1210-1216.Allergic AsthmaPivotal Trial(s) -
20040401 Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma
Holgate ST, Chuchalin AG, Herbert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632-638.Allergic AsthmaPivotal Trial(s) -
20030801 Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90.Allergic AsthmaPivotal Trial(s) -
20030801 Omalizumab is effective in the long-term control of severe allergic asthma.
Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91:154-159.Allergic AsthmaPivotal Trial(s) -
20020701 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma.
Buhl R, Solèr M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20:73-78.Allergic AsthmaPivotal Trial(s) -
20010801 The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61.Allergic AsthmaPivotal Trial(s) -
20010801 Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)
Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108(2).Allergic AsthmaPivotal Trial(s)
No results
Try resetting the filters or selecting another category.
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT
Clinical Trials
Find information about active clinical research for XOLAIR at ClinicalTrials.gov and information about our research at Genentech Clinical Trials.
Additional Resources
For additional information or assistance regarding Xolair® use the links below.
Connect with a Medical Science Liaison
Browse the Genentech Medical Information Library